Steatohepatitis/Metabolic Liver Disease News

Both the fatty liver inhibition of progression algorithm and the steatosis activity and fibrosis scoring system identified distinct clinical and biological profiles of disease severity among patients with suspected nonalcoholic fatty liver disease.

Akero Therapeutics announced that it has completed enrollment for a phase 2a study of AKR-001, the company’s FGF21 analog candidate for the treatment of nonalcoholic steatohepatitis, according to a press release.

The American College of Gastroenterology released a new guideline on disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries, which can lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma.

Poxel announced positive safety, tolerability and pharmacokinetic results from a phase 1b multiple ascending dose trial of PXL065, a deuterium-stabilized R-stereoisomer of Actos under investigation for nonalcoholic steatohepatitis, according to a press release.

Boehringer Ingelheim and Pharmaxis announced that development of BI 1467335 for the treatment of nonalcoholic steatohepatitis would be discontinued, according to a press release.

Excitement has peaked this year for potential nonalcoholic steatohepatitis therapies as many more studies have revealed positive outcomes in either resolution of nonalcoholic steatohepatitis without worsening of fibrosis or reduction in fibrosis stage without worsening of nonalcoholic steatohepatitis.

A novel combinations of glycans, lipids and hormonal variables can simultaneously diagnose the presence of nonalcoholic fatty liver or nonalcoholic steatohepatitis with up to 90% accuracy, according to findings published in Metabolism Clinical and Experimental.

Results from the phase 2 ATLAS study showed that neither monotherapy nor combined therapy with cilofexor reached the endpoint of significant improvement in fibrosis stage without worsening of nonalcoholic steatohepatitis, according to a press release from Gilead Sciences.

Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according to data presented at the American Society of Hematology meeting.

The GALAD score was superior to individual serum markers in detecting hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, according to a case-control study published in Clinical Gastroenterology and Hepatology Journal.